Vericel (VCEL) Amortization of Deferred Charges (2019 - 2026)
Vericel (VCEL) posted Amortization of Deferred Charges of $1.4 million for Q2 2026, up 2.2% sequentially from $1.4 million in Q1 2026, and up 5.68% YoY from $1.3 million in Q2 2025.
Powered by 
Analysis
Vericel (VCEL) Amortization of Deferred Charges (2019 - 2026) Analysis & Trends
Vericel has reported Amortization of Deferred Charges for 6 years, with the latest figure at $1.4 million in Q2 2026.
- Quarterly Amortization of Deferred Charges rose 5.68% year-over-year to $1.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $5.4 million (down 7.92% YoY) and the FY2025 annual result came in at $5.4 million, down 19.56% from the prior year.
- Amortization of Deferred Charges advanced to $1.4 million in Q2 2026 per VCEL's latest filing, from $1.4 million in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $1.8 million in Q3 2023 and troughed at $965000.0 in Q3 2022.
- A 5-year average of $1.4 million and a median of $1.4 million in 2023 frame the typical range for Amortization of Deferred Charges.
- The sharpest annual moves came in 2023 and 2025: Amortization of Deferred Charges jumped 89.12% in 2023, then dropped 22.76% in 2025.
- Over 5 years, Amortization of Deferred Charges stood at $1.1 million in 2022, then soared by 61.43% to $1.8 million in 2023, then retreated by 15.01% to $1.5 million in 2024, then retreated by 11.64% to $1.3 million in 2025, then rose by 4.42% to $1.4 million in 2026.
- According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $1.4 million, $1.4 million, and $1.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 54,000.00 |
| Mar 31, 2026 | 54,000.00 |
| Dec 31, 2025 | 54,000.00 |
| Sep 30, 2025 | 53,000.00 |
| Jun 30, 2025 | 54,000.00 |
| Mar 31, 2025 | 54,000.00 |
| Dec 31, 2024 | 54,000.00 |
| Sep 30, 2024 | 53,000.00 |
| Jun 30, 2024 | 54,000.00 |
| Mar 31, 2024 | 54,000.00 |
| Dec 31, 2023 | 54,000.00 |
| Sep 30, 2023 | 53,000.00 |
| Jun 30, 2023 | 54,000.00 |
| Mar 31, 2023 | 54,000.00 |
| Dec 31, 2022 | 54,000.00 |
| Sep 30, 2022 | 36,000.00 |
| Sep 30, 2021 | -2.33 Mn |
| Jun 30, 2021 | 1.15 Mn |
| Mar 31, 2021 | 1.17 Mn |
| Dec 31, 2020 | -3.31 Mn |